Vincent C Lombardi1, Svetlana F Khaiboullina, Albert A Rizvanov. 1. Department of Biochemistry and Molecular Biology, University of Nevada School of Medicine, University of Nevada, Reno, NV, USA; Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Republic of Tatarstan, Russian Federation.
Abstract
BACKGROUND: Plasmacytoid dendritic cells (pDCs) are multifunctional bone-marrow-derived immune cells that are key players in bridging the innate and adaptive immune systems. Activation of pDCs through toll-like receptor agonists has proven to be an effective treatment for some neoplastic disorders. MATERIALS AND METHODS: In this mini-review, we will explore the fascinating contribution of pDCs to neoplastic pathology and discuss their potential utilization in cancer immunotherapy. RESULTS: Current research suggests that pDCs have cytotoxic potential and can effectively induce apoptosis of tumour-derived cells lines. They are also reported to display tolerogenic function with the ability to suppress T-cell proliferation, analogous to regulatory T cells. In this capacity, they are critical in the suppression of autoimmunity but can be exploited by tumour cells to circumvent the expansion of tumour-specific T cells, thereby allowing tumours to persist. CONCLUSION: Several forms of skin cancer are successfully treated with the topical drug Imiquimod, which activates pDCs through toll-like receptor 7 engagement. Additionally, pDC-based anticancer vaccines have shown encouraging results for the treatment of melanoma in early trials. Future studies regarding the contributions of pDCs to malignancy will likely afford many opportunities for immunotherapy strategies.
BACKGROUND: Plasmacytoid dendritic cells (pDCs) are multifunctional bone-marrow-derived immune cells that are key players in bridging the innate and adaptive immune systems. Activation of pDCs through toll-like receptor agonists has proven to be an effective treatment for some neoplastic disorders. MATERIALS AND METHODS: In this mini-review, we will explore the fascinating contribution of pDCs to neoplastic pathology and discuss their potential utilization in cancer immunotherapy. RESULTS: Current research suggests that pDCs have cytotoxic potential and can effectively induce apoptosis of tumour-derived cells lines. They are also reported to display tolerogenic function with the ability to suppress T-cell proliferation, analogous to regulatory T cells. In this capacity, they are critical in the suppression of autoimmunity but can be exploited by tumour cells to circumvent the expansion of tumour-specific T cells, thereby allowing tumours to persist. CONCLUSION: Several forms of skin cancer are successfully treated with the topical drug Imiquimod, which activates pDCs through toll-like receptor 7 engagement. Additionally, pDC-based anticancer vaccines have shown encouraging results for the treatment of melanoma in early trials. Future studies regarding the contributions of pDCs to malignancy will likely afford many opportunities for immunotherapy strategies.
Authors: Chunmei Fu; Peng Peng; Jakob Loschko; Li Feng; Phuong Pham; Weiguo Cui; Kelvin P Lee; Anne B Krug; Aimin Jiang Journal: Proc Natl Acad Sci U S A Date: 2020-09-02 Impact factor: 11.205
Authors: Mahua Dey; Alan L Chang; Jason Miska; Derek A Wainwright; Atique U Ahmed; Irina V Balyasnikova; Peter Pytel; Yu Han; Alex Tobias; Lingjiao Zhang; Jian Qiao; Maciej S Lesniak Journal: J Immunol Date: 2015-05-29 Impact factor: 5.422
Authors: Antoni Ribas; Theresa Medina; John M Kirkwood; Yousef Zakharia; Rene Gonzalez; Diwakar Davar; Bartosz Chmielowski; Katie M Campbell; Riyue Bao; Heather Kelley; Aaron Morris; David Mauro; James E Wooldridge; Jason J Luke; George J Weiner; Arthur M Krieg; Mohammed M Milhem Journal: Cancer Discov Date: 2021-12-01 Impact factor: 39.397